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Abstract
Alternative splicing of pre-mRNA is a critical stage of gene regulation in response to 
environmental stimuli. Here we show that DAZAP1, an RNA binding protein involved in 
mammalian development and spermatogenesis, promotes inclusion of weak exons through specific 
recognition of diverse cis-elements. The C-terminal proline-rich domain of DAZAP1 interacts 
with and neutralizes general splicing inhibitors, and is sufficient to activate splicing when 
recruited to pre-mRNA. This domain is phosphorylated by the MEK/Erk pathway and this 
modification is essential for the splicing regulatory activity and the nuclear/cytoplasmic 
translocation of DAZAP1. Using mRNA-seq we identify endogenous splicing events regulated by 
DAZAP1, many of which are involved in maintaining cell growth. Knockdown or over-expression 
of DAZAP1 causes a cell proliferation defect. Taken together, these studies reveal a molecular 
mechanism that integrates splicing control into MEK/Erk regulated cell proliferation.
Introduction
Alternative splicing of pre-mRNA is a key regulatory step in gene expression to increase 
proteome diversity in higher eukaryotes 1–4. Generally, alternative splicing is regulated by 
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multiple cis-acting splicing regulatory elements (SREs) that recruit trans-acting splicing 
factors to promote or inhibit the use of nearby splice sites 5,6. Depending on their location 
and activity, the SREs are conveniently classified as exonic splicing enhancers or silencers 
(ESEs or ESS) and intronic splicing enhancers or silencers (ISEs or ISSs). Many splicing 
factors function in a modular fashion with an RNA binding module to recognize pre-mRNA 
and a functional module to control splicing. For example, the serine/arginine-rich (SR) 
proteins are known to bind ESE with RNA recognition motifs (RRMs) and promote exon 
inclusion with RS domains 7, whereas the hnRNP A family can bind to ESS with RRMs and 
inhibit splicing with Gly-rich domains 8,9. However, when recruited to intronic regions, both 
RS domains and Gly-rich domains can inhibit splicing 10,11. Since many splicing factors 
have a similar domain architecture containing RNA binding domains and low complexity 
fragments, it is an intriguing idea that they may also control splicing in a modular fashion 
through some novel functional domains.
As a key regulatory step of gene expression, alternative splicing is regulated by 
environmental cues through various signaling pathways that control the levels and activities 
of splicing factors 12. The MEK/Erk kinase cascade is a central component of a mitogen-
activated pathway that communicates growth signals from the cell surface to the nucleus. 
The MEK/Erk pathway promotes cell proliferation mainly by mediating the phosphorylation 
of major transcription factors such as CREB and Myc to change the transcription of many 
targets 13. In addition, this pathway also phosphorylates and inactivates the apoptotic 
regulators (e.g., BAD) to control cell death 14. It was reported that the MEK/Erk pathway 
affected alternative splicing of CD44 by phosphorylating and activating Sam68 15–17, and a 
regulatory feedback was found to link Ras activation with splicing of a different alternative 
exon in CD44 18. The MEK/Erk pathway was also found to regulate the splicing of FGF 
receptor in response of TGF-beta stimulation 16. In a related study, the activation of EGF 
was found to regulate splicing by phosphorylating SR proteins through PI3K/Akt/SRPK 
branch of this pathway 19.
DAZ associated protein 1 (DAZAP1) is an hnRNP protein originally identified as binding 
partner of DAZ (deleted in azoospermia) 20,21. It is homologous to hnRNP A1 and D family 
that contain two N-terminal RRM domains followed by a low complexity C-terminal 
domain (CTD) 22 (Supplementary Fig. 1a). DAZAP1 is highly conserved among vertebrates, 
with 95% amino acid identity for the entire protein among mammals and 100% identity in 
the RRM region from human to frog, suggesting that it may recognize similar RNA motifs 
across species to control key steps in RNA metabolism (Supplementary Fig. 1b). DAZAP1 
was shown to bind AAUAG and GU1–3 AG in vitro but its endogenous RNA targets have 
not been identified on a genomic scale 23. DAZAP1 was found in different cellular 
compartments depending on cell and tissue types: it is mainly localized in cytoplasm of 
oocytes from Xenopus or mammals 17,24, but is mostly nuclear except in the elongated 
spermatids during spermatogenesis 20,25,26. In cultured cells, DAZAP1 was mainly detected 
in nucleus but also translocated to cytoplasmic/mitochondrial compartment in response to 
external stimuli 27. This protein was shown to be required in normal development and 
spermatogenesis in mice, as DAZAP1 deletion caused smaller body size, premature death 
and spermatogenesis arrest 26. The molecular function of DAZAP1 remains unclear, 
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although there is evidence showing that it affects mRNA localization 24, alternative 
splicing 28, and translation 29. DAZAP1 was reported to bind ESSs together with hnRNP 
A1/A2 in a BRCA1 exon 18 mutant and was believed to inhibit splicing 30. In another 
example, DAZAP1 and hnRNP A1 were found to bind an Alu-derived fragment in an ATM 
intron and affect splicing in opposite ways 31. However, the general role of DAZAP1 in 
regulating splicing has not been systematically studied, and its affinity for in vivo RNA 
substrates as well as protein interaction partners has not been examined in detail.
We previously identified DAZAP1 as a binding protein for several ISEs or ISSs in human 
cells 10,28. Here we thoroughly examine the direct binding of DAZAP1 to various RNA 
elements and to other hnRNPs, and further study the general activity of DAZAP1 in splicing 
regulation. We show that DAZAP1 can enhance splicing from either an intronic or exonic 
context, and such activity can be achieved through two mechanisms. We use mRNA-seq to 
identify hundreds of endogenous splicing events controlled by DAZAP1, many of which are 
involved in maintaining cell growth. We further study how DAZAP1 activity can be 
controlled through phosphorylation by the MEK/Erk pathway, and determine the function of 
DAZAP1 in mediating cell proliferation. Taken together, this study provides a 
comprehensive picture of DAZAP1-mediated splicing regulation, and reveals an integrated 
model that alternative splicing can be controlled through a MEK/Erk/DAZAP1 pathway to 
respond to outside stimuli.
Results
Intricate interaction network among RNA and hnRNPs
In an unbiased screen we identified multiple RNA motifs that function as general splicing 
enhancers or silencers from the intronic region 10,28. Here, we use RNA affinity 
chromatography to identify protein factors that bind to each group of intronic splicing 
enhancers or silencers, and identify DAZAP1 among the binding factors for one ISE and 
three ISS groups (ISE group F and ISS groups F, H and I, Fig. 1a). The RNA affinity 
purification also identifies other proteins in the hnRNP A1 and D family as binding partners 
for ISSs (Fig. 1a). There are two possibilities to explain the interaction between DAZAP1 
with multiple RNA targets: First, DAZAP1 forms a protein-protein complex with other 
hnRNPs that bind to these RNA elements directly, thus DAZAP1 recognizes RNAs through 
a piggyback mechanism. Second, there is direct binding of DAZAP1 to different RNA 
elements with diverse consensus motifs.
To distinguish these two models, we performed surface plasmon resonance (SPR) 
measurements to determine direct RNA-protein binding (Fig. 1b–e). We purified the 
recombinant human DAZAP1 protein to homogeneity using Ni-NTA chromatography 
(Supplementary Fig. 2), and chemically synthesized the biotinylated RNAs representing the 
consensus motif of each group. We found that DAZAP1 directly binds to three ISS groups 
(F, H and I) and one ISE group (F) with nanomolar affinities (Supplementary Table 1), 
suggesting that the co-purification of DAZAP1 with intronic SREs reflected direct RNA-
protein interactions. The ISS group F and H were preferably bound by DAZAP1 compared 
to group I, consistent with the observation that mouse DAZAP1 was shown to bind AAUAG 
and GU1–3 AG sequences in vitro 23. The three ISS groups also bind to proteins in the 
Choudhury et al. Page 3













hnRNP A1 and D family (A0 A1 A2, D, DL) with similar affinities 10 (Supplementary Table 
1), consistent with our finding that the interactions between splicing factors and SREs 
usually form an intricate network with overlapping binding specificities 10.
DAZAP1 has two N-terminal RRMs that typically bind to single stranded RNA in a 
sequence specific manner (Fig. 1f), thus we further examined if both RRMs in DAZAP1 are 
required for the specific RNA binding. We use the ISS group F as exemplar to measure its 
direct binding to the RRM1, RRM2 or both RRMs (Fig. 1g to i). We find that both RRMs 
are required for binding to the RNA target, as the individual RRM showed minimal 
interaction (the Kd calculation was not reliable in this range). The binding affinity of 
2xRRM fragment is similar to the entire protein (Fig. 1j). This result suggests a co-operative 
binding model for two RRM domains, a mechanism consistent with that of hnRNPA1 where 
the inter-domain interaction between two RRMs is critical for RNA binding 32,33,34.
DAZAP1 interacts with proteins in the hnRNP A1 family
We further examine the protein-protein interaction of DAZAP1 with other hnRNPs that co-
purified with DAZAP1 during the RNA affinity chromatography. Using isothermal 
calorimetry experiments (ITC) in the absence of RNA, we find that DAZAP1 directly 
interacts with purified recombinant hnRNPs (hnRNPA0, A1, A2 and D; hnRNP DL forms 
self-aggregates at the high concentration needed for ITC) with dissociation constant (Kd) in 
micromolar range (Fig. 2a, and Supplementary Fig. 2). This binding has a 1:1 stoichiometry 
as judged by fitting the ITC data with Langmuir binding model 35. The bindings of 
DAZAP1 to other hnRNPs was mediated by the proline-rich CTD of DAZAP1, as the CTD 
itself had similar binding affinity to other hnRNPs as the full-length DAZAP1 (Fig. 2b). The 
N-terminal 2xRRM domain of DAZAP1 did not interact with other hnRNPs, as we fail to 
detect any significant binding signals using ITC assay (Fig. 2c). The above results suggest 
that the binding of DAZAP1 to hnRNPs (A0, A1, A2 or D) is mediated only by the proline-
rich low complexity CTD rather than by the RRM domains as reported previously 36. Our 
finding is consistent with the reports that the low complexity fragments in RNA binding 
proteins tend to form fibers with each other 37–39. The binding thermograms indicated that 
the protein interactions are endothermic and thus are mostly mediated through hydrophobic 
interactions. Consistently, it was shown that polyproline in elastin partially assumed a 
hydrophobic structure of polyproline II (PPII) helix 40.
DAZAP1 promotes splicing of weak exons
Since DAZAP1 interacts with multiple intronic SREs (both ISSs and ISE), we next 
examined if this binding could affect alternative splicing. We took advantage of a MS2 
tethering system where a single MS2 hairpin site is inserted downstream of an alternative 
exon (exon 2 of Chinese hamster DHFR gene) 28. The inclusion of the alternative exon is 
then examined with co-expression of different proteins fused with the MS2 coat protein 
(Fig. 3a). We find that when tethered into the downstream intron, DAZAP1 could promote 
splicing of the upstream exon as compared to the MS2 coat protein alone (Fig. 3a), 
consistent with our finding that DAZAP1 is responsible for the ISE activity in group F 28. 
This activity is comparable to another splicing factor hnRNP H that is known to enhance 
splicing from introns (Fig. 3a). Interestingly, tethering of the CTD of DAZAP1 (aa 191–
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470) also enhances splicing with a similar activity (Fig. 3a), suggesting that the CTD can act 
as a functional domain to promote splicing from introns.
To study how DAZAP1 was affecting splicing from an exonic context, we used a series of 
splicing reporters with test exons of various strengths (Fig. 3b, reporters A to E). All 
reporters were inserted with an exonic MS2 site for tethering splicing factors in the test 
exon 41. The co-expression of MS2-DAZAP1 enhanced the splicing of weak exons when 
binding to the exonic region, and this activity could be recapitulated with the CTD of 
DAZAP1 (Fig. 3b). DAZAP1 (or the CTD) had strong activity in promoting exons with a 
weak 5′ splice site (reporters D and E), as smaller increases were observed in the reporters 
with a stronger exon (reporter A and B). This 5′ splice site-dependent activity is not due to 
the different basal levels of exon inclusion, as the reporter C with a strong 5′ splice site but a 
mutated branch-point site/polypyrimidine tract had similar basal inclusion level but was 
weakly promoted by DAZAP1 (Fig. 3b, lanes 7 to 9). The splice site strength-dependent 
activity is also found for hnRNP L and hnRNP H promoting weak exon inclusion 41,42, and 
our findings suggest that this might be a general property for many other splicing factors.
CTD of DAZAP1 binds and antagonizes hnRNPA1
The above results suggest that the proline-rich CTD of DAZAP1 is a splicing regulatory 
module similar to RS domains or Gly-rich domains in that it can control splicing when 
recruited to different pre-mRNA locations 43. Since DAZAP1 and its CTD were found to 
interact with the members of hnRNP A1 family (Fig. 2), we further tested if such 
interactions could play a role in the splicing enhancing activity of DAZAP1. The binding 
between DAZAP1 and hnRNP A1 was first examined in cell lysates by co-
immunoprecipitation after RNase A treatment, and we find that DAZAP1 can indeed bind 
hnRNP A1 in cultured cells (Fig. 4a, lane 6). In addition, this binding is mediated by 
interaction of the proline-rich CTD of DAZAP1 to the Gly-rich domain of hnRNP A1, as the 
two domains can be individually co-precipitated (lanes 7 to 9). This interaction is further 
confirmed with co-immunoprecipitation using endogenous DAZAP1 antibody, in which 
hnRNPA1, but not a control splicing factor SRSF1, is found to co-precipitate with DAZAP1 
(Supplementary Fig. 3).
The results in Fig. 3 and earlier studies 28 indicate that DAZAP1 can promote splicing from 
both intronic and exonic locations, opposite from the activity of hnRNP A1. Therefore, we 
examined if the CTD domain can antagonize the splicing inhibitory activity of hnRNP A1. 
We use a splicing reporter with hnRNP A1 binding site (ISS group F) in an alternative exon, 
and co-express this with hnRNP A1 and/or the CTD of DAZAP1 (Fig. 4b). As expected, the 
hnRNP A1 alone can inhibit exon splicing, whereas the CTD of DAZAP1 alone hass no 
effect on splicing (lanes 1 to 3, Fig. 4b). However, the co-expression of the CTD of 
DAZAP1 neutralized the splicing inhibition by hnRNP A1 in a dose dependent manner, 
suggesting that the binding of the CTD to hnRNP A1 can block hnRNP A1 activity. This 
antagonistic activity between DAZAP1-CTD and hnRNP A1 is also confirmed in 
endogenous genes that contain hnRNP A1/DAZAP1 binding sites near an alternative exon 
(Supplementary Fig. 4).
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Because hnRNP A1 inhibits splicing through its Gly-rich domain 8,43, we further tested if 
the direct binding of DAZAP1 CTD to this domain can revert the splicing inhibition. We 
tethered Gly-rich domain of hnRNPA1 to an alternative exon inserted with MS2 hairpin, and 
co-expressed it with the CTD of DAZAP1 (Fig. 4c, top panel). As predicted, the MS2-
Gly(hnRNP A1) inhibits splicing when recruited to the MS2 site whereas the CTD of 
DAZAP1 had no effect. Co-expression of the CTD (DAZAP1) with MS2-Gly(hnRNP A1) 
again neutralized the splicing inhibitory activity of the Gly-rich domain of hnRNP A1 in a 
dose-dependent manner, confirming that direct binding of these two domains plays 
important roles in mediating their activities (Fig. 4c). The Gly-rich domain of hnRNP A1 is 
believed to mediate the cooperative spreading of A1 along pre-mRNA 44,45, and we 
speculate that the binding of the CTD of DAZAP1 may interfere with such spreading and 
thus antagonize hnRNP A1 activity.
DAZAP1 regulates splicing of many genes in kinase pathways
To examine how DAZAP1 affects gene expression in a global scale, we performed mRNA-
seq with Illumina platform using 293 cells depleted of DAZAP1 by shRNA (Fig. 5a). By 
sequencing three libraries (one control and two RNAi lines with different shRNAs), we 
obtained in total ~500 million pair-end reads of 100-nt, which were mapped to the human 
genome with MapSplice and further analyzed with Cufflink 46,47. We find that the 
expression levels of only four genes are significantly changed, with DAZAP1 being the 
most significantly decreased (with adjusted p value of 1.1E-07, Supplementary Data 1). In 
addition, two genes (MAGEA12 and ZNF804A) are significantly increased in expression 
and the level of one pseudogene (RP11-393N4.2) is decreased (cutoff of adjusted p 
value=0.05). If we relax the cutoff of the adjusted p value to 0.25, 11 genes are found to 
change expression levels among 17435 genes with enough read coverage for statistical 
analysis (some validated in Supplementary Fig. 5), suggesting that DAZAP1 had little effect 
on gene transcription or mRNA degradation.
We further examined the splicing patterns in DAZAP1 knockdown cells using the MISO 
package to analyze mapped reads 48, and identify splicing events with an obvious change 
(≥0.1) in PSI values (percent-spliced-in) at a Bayes factor cutoff of 20. We find that a large 
number of alternative splicing events are significantly changed upon RNAi of DAZAP1, 
with the read tracks of two examples and the number of different types of events being 
shown (Fig. 5b, changes of all splicing events were listed in Supplementary Data 2). The 
most abundant type of alternative splicing events affected by DAZAP1 is skipped exons 
(SE). This observation that DAZAP1 mainly affects the levels of splicing isoforms rather 
than the total transcripts is expected, as DAZAP1 does not seem to bind DNA but rather 
affects RNA metabolism.
We further analyzed all the alternative splicing events affected by DAZAP1 using gene 
ontology analysis (GO), and find that the genes affected by DAZAP1 are clustered 
functionally into several main groups including alternative splicing, protein phosphorylation 
and acetylation, gene transcription (repressors and coiled coil domain containing proteins), 
ATP binding (Fig. 5c). The largest group, alternative splicing, is an expected result because 
DAZAP1 is a splicing factor and these target genes are originally selected based on their 
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significant change in splicing levels. Protein phosphorylation (and related ATP binding) and 
acetylation are the next largest functional groups, suggesting that DAZAP1 is closely 
involved in regulating cellular signaling pathways. We then extracted all the DAZAP1 
targets in the phosphoprotein and acetylation groups, and find that many of these targets 
were functionally connected into well-linked interaction networks as judged by a functional 
network analysis using STRING (Search Tool for the Retrieval of Interacting Genes/
Proteins) (Fig. 5d). Interestingly, the largest interaction network contained many genes in 
cell signaling pathways that control gene transcription, cell cycle and cell proliferation (Fig. 
5d). This network also includes a small group of metabolic enzymes involved in ATP 
synthesis, suggesting that DAZAP1 may affect energy metabolism of cells.
Subsequent analysis of splicing changes indicate that the splicing of ~60% of genes is 
positively regulated by DAZAP1 (decreased exon inclusion level or PSI value after 
DAZAP1 RNAi), consistent with the role of DAZAP1 to promote exon inclusion when 
directly binding to pre-mRNA. We further tested the results of mRNA-seq by randomly 
selecting several targets and assaying their splicing with RT-PCR in cells with 
overexpression or knockdown of DAZAP1 (Supplementary Fig. 6a and b). As shown in the 
example of WAC, a gene encoding WW domain-containing adapter protein with coiled-coil 
to regulating H2B monoubiquitination and gene transcription 49, DAZAP1 over-expression 
promotes inclusion of exon 7 to produce more full-length canonical isoforms whereas RNAi 
of DAZAP1 has the opposite effect (Fig. 5e). We further validated additional positively 
regulated DAZAP1 targets involved in cell proliferation and RNA processing pathways 
(Fig. 5f). For example, the SRSF6 gene encodes a splicing factor that can enhance 
proliferation of lung epithelial cells 50, and MELK encodes a protein kinase that can regulate 
cell cycle progression by binding and phosphorylating CDC25B 51. We obtained reciprocal 
splicing changes for these candidate genes in cells with over-expression and knockdown of 
DAZAP1 (Fig. 5f and Supplementary Fig. 6), suggesting that mRNA-seq indeed can reliably 
identify endogenous splicing events regulated by DAZAP1. This splicing regulation activity 
of DAZAP1 is comparable to a well-established splicing factor SRSF1 (Supplementary Fig. 
6c). In addition, knock-down of DAZAP1 with shRNA in HeLa cells shows similar effects 
on splicing of DAZAP1 targets, indicating that the splicing regulation activity of DAZAP1 
is not tissue or cell type specific (Supplementary Fig. 6d).
We also analyzed sequences around these DAZAP1 regulated exons to examine if they 
contain the RNA motifs recognized by DAZAP1. We extracted sequences within or at the 
downstream of the skipped exons that were positively or negatively regulated by DAZAP1, 
and compared the relative abundance of the DAZAP1 binding motifs (three ISS groups and 
one ISE group) with the control exon set that were not affected by RNAi of DAZAP1. Using 
an enrichment score of small motifs 52, we find, as expected, that DAZAP1 binding motifs 
are more enriched in exons positively regulated by DAZAP1 (i.e. exon inclusion was 
decreased by DAZAP1 RNAi) but are slightly depleted in exons negatively regulated by 
DAZAP1 (Fig. 5g).
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DAZAP1 is regulated by phosphorylation through MEK/Erk
DAZAP1 was shown to be phosphorylated by Erk (extracellular-signal-regulated protein 
kinase) at two threonines (Thr269 and Thr315) in the proline-rich CTD 53. However, the 
functional consequence is unclear, as this phosphorylation does not affect the ability of 
DAZAP1 to interact with other proteins or RNA 29,36. We generated MS2 fusion proteins 
using a series of truncated fragments of DAZAP1 CTD, and co-expressed them with the 
splicing reporter containing an exonic MS2 site (Fig. 6a, left panel). As controls, the full 
length DAZAP1 and intact CTD enhanced splicing when tethered to the exon (Fig. 6a, 
constructs 1 and 2). Similarly the CTD truncations containing the two threonine 
phosphorylation sites can also promote splicing (Fig. 6a constructs 3 and 4). In contrast, the 
truncated proteins lacking one or both of these phosphorylation sites loose their activity in 
enhancing splicing (lanes 5 to 7), indicating that the N-terminal fragment of the DAZAP1 
CTD (including both phosphorylation sites) is critical to its activity.
It was previously found that the phosphorylation of DAZAP1 at Thr-269 and Thr-315 by 
Erk1/2 does not disrupt its interaction with the AU rich RNA elements but induces its 
dissociation from DAZ 53. However, this phosphorylation does not affect the translation 
enhancer activity of DAZAP1 29. Given that both threonines are required for splicing 
activity of DAZAP1 (Fig. 6a), we predict that the MEK/Erk pathway can affect the splicing 
regulatory activity of DAZAP1 by mediating CTD phosphorylation (Fig. 6b, right panel). To 
test this, we treated 293T cells with either an Erk activator (PMA, phorbol 12-myristate 13-
acetate) or a well characterized MEK kinase inhibitor U0126 and determined if such 
treatment could affect the DAZAP1 activity in the tethering experiment (Fig. 6b, right 
panel). As expected, binding of MS2-DAZAP1 to the test exon promoted splicing of that 
exon (Fig. 6b, lane 1 vs 3, or lane 5 vs 7), whereas Erk-activation by PMA had no obvious 
effect on the splicing outcome (lane 3 vs 4). However, inhibition of MEK/Erk pathway by 
U0126 significantly decreased the splicing activation by DAZAP1 (lane 7 vs 8), suggesting 
the phosphorylation of DAZAP1 by MEK/Erk is necessary for its splicing regulatory 
activity. Consistently, the phosphomimetic mutant of DAZAP1 (T2D; T269D/T315D) also 
promotes splicing, but its activity is not affected by MEK inhibition with U0126 
(Supplementary Fig. 7a).
To directly examine the phosphorylation status of DAZAP1, we used Phostag™ gels where 
phosphorylated proteins can be separated due to binding of Phos-tag molecules 54. The 
levels of phospho-DAZAP1 species were decreased by the addition of two different of MEK 
inhibitors, suggesting that DAZAP1 phosphorylation is mediated by MEK/Erk activation 
(Fig. 6c). Consistent with these results, we found that the mutation of the two DAZAP1 
threonine sites (T2A; T269A/T315A) greatly decreased its activity in promoting the 
inclusion of alternative exon (Fig. 6d), again indicating that the threonine phosphorylation of 
DAZAP1 by Erk1/2 is required for its activity. In addition, the over-expression of wild type 
DAZAP1 or T2D mutant, but not the T2A mutant, promoted splicing of endogenous 
DAZAP1 target (Supplementary Fig. 7b). The inhibition of MEK/Erk pathway by U0126 
also decreases the splicing of the endogenous targets of DAZAP1 (FIPIL1 and MELK), and 
such splicing inhibition was not observed in the DAZAP1 knockdown cells (Fig. 6e). Taken 
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together, these results cumulatively show that the MEK/Erk pathway controls alternative 
splicing through mediating the phosphorylation of a general splicing factor DAZAP1.
Phosphorylation of DAZAP1 by Erk regulates its localization
Like many splicing factors, DAZAP1 is known to shuttle between the nucleus and 
cytoplasm 20,27,55,56, although it was mostly detected within the nucleus of cultured cells or 
spermatocytes 20,25,27 and in the cytoplasm of oocytes 17,24. We further examined if the 
localization of DAZAP1 is affected by its phosphorylation using immunofluoresecence in 
cells treated with MEK inhibitors. We find that in control cells treated with DMSO, 
DAZAP1 localizes in the nucleus as speckled structures in the majority (~75%) of cells, 
whereas in some cells it can be found in both nuclear and cytoplasmic compartments (Fig. 6f 
upper panels and Supplementary Fig. 8a). Consistent with our finding, DAZAP1 also co-
localizes with hnRNP A1 and A2 (Fig. 6f and Supplementary Fig. 8c and d), which are 
known nucleo-cytoplasmic shuttling splicing factors that interact with DAZAP1 (Fig. 2 and 
4a). Co-localization was also confirmed with antibody against endogenous DAZAP1 (Fig. 
6g, Supplementary Fig. 8c and d). However the DAZAP1 localization is distinct from the 
nuclear speckles containing SC35 (SFSR2), an SR protein that promotes splicing 
(Supplementary Fig. 8b). Upon treatment with MEK inhibitor, most of the DAZAP1 
proteins were localized in perinuclear/cytoplasmic regions (~80% of cells had cytoplasmic 
or nuclear/cytoplasmic DAZAP1 localization), while the hnRNPA1 is still found to be 
nuclear (Fig. 6f), suggesting that Erk-mediated protein translocation is specific to DAZAP1 
rather than a general phenomenon for shuttling splicing factors. Serum starvation followed 
by the PMA treatment did not significantly alter the nuclear localization of DAZAP1 in 
HEK 293T cells. (Supplementary Fig. 7c).
To further confirm this result, we mutated the two threonine residues of DAZAP1 
phosphorylated by Erk1/2 and examined localization of the mutant protein. While the 
majority of wild type and T2D DAZAP1 is in the nucleus, most T2A mutants are found in 
both the nucleus and cytoplasm (Supplementary Fig. 9), which is consistent with our 
observations using a MEK inhibitor (Fig. 6f). The inefficient localization of T2A mutant in 
the nucleus is also consistent with our finding that this mutation decreased the DAZAP1 
splicing regulation activity (Fig. 6d). Taken together these results suggest that the Erk-
mediated phosphorylation probably controls the splicing regulatory activity of DAZAP1 via 
affecting its sub-cellular localization. In a recent study of mouse DAZAP1, Sasaki et al 
found that acetylation of Lys150 in the second RRM of DAZAP1 can affect its nucleo-
cytoplasmic translocation 55. We found that such translocation my also be regulated by 
phosphorylation in the CTD of DAZAP1, suggesting the subcellular localization of 
DAZAP1 is controlled at multiple levels through different mechanisms.
DAZAP1 controls cell proliferation
Because the MEK/Erk pathway plays a key role in regulating cell growth and malignant 
transformation, our observations suggest that DAZAP1-mediated splicing regulation might 
have an influence on cell growth. To test this, we generated stable cell lines with over-
expressed DAZAP1 using a lung cancer cell line H157 (Fig. 7a) and HEK 293T cells 
(Supplementary Fig. 10a), and found that the wild type and phosphomimetic DAZAP1 
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(T2D) inhibit cell growth in colony formation assays, while the T2A mutant had little effect 
(Figs. 7b and Supplementary Fig. 10a). In addition, DAZAP1 expression also decreased 
anchorage independent growth of H157 cells as judged by soft agar colony assays (Fig. 7c). 
We also find that DAZAP1 can inhibit cell migration in a wound-healing assay (Fig. 7d), 
suggesting that DAZAP1-dependent splicing control may affect cell growth and migration.
The decrease of cell growth in culture is commonly caused by increased apoptosis or 
disruption of cell cycle regulation, thus we tested if the DAZAP1 over-expression could 
affect cell cycle progression. When we measured the fractions of cells in different cell cycle 
stages using flow cytometry, we find that the DAZAP1 over-expression slightly increased 
(or did not change) the relative fraction of cells in G1 phase vs. G2/M phase (Fig. 7e). We 
further used double-thymidine block to synchronize cells in different cell cycle stages, and 
find that DAZAP1 protein level is regulated during the cell cycle. Compared to the 
asynchronized culture, the DAZAP1 level is higher in G2/M phase but is decreased at the 
G1/S stage (Fig. 7f), suggesting that DAZAP1 protein expression/stability may be regulated 
during the cell cycle. Taken together these data indicate that the expression level of 
DAZAP1 is critical to cell growth and proliferation.
Discussion
We initiated the mechanistic investigation of DAZAP1 by studying its interactions with 
RNA elements and other splicing factors. These studies further reveal its activity as a 
splicing activator and the underlying mechanisms of its regulation. Through a genome-wide 
analysis, we identify hundreds of DAZAP1-controled alternative splicing events, many of 
which are involved in protein phosphorylation pathways. Finally, we find that the MEK/Erk 
signaling pathway can control the activity and localization of DAZAP1 by mediating its 
phosphorylation. This study leads to an integrated model in which the MEK/Erk pathway 
activated by environmental cues can phosphorylate DAZAP1 to induce its translocation to 
the nucleus, and DAZAP1 in turn regulates cell proliferation by promoting splicing of 
multiple genes through two different mechanisms: by binding directly to cis-acting SREs 
and enhancing splicing with proline-rich CTD and by competing with and neutralizing 
splicing inhibitors in the hnRNP A1 family (Fig. 7g).
DAZAP1 is found to recognize both ISSs and ISEs, causing an apparent paradox concerning 
how it controls splicing from introns. This paradox can be resolved by the finding that trans-
acting splicing factors and cis-acting SREs usually are connected by a complex network of 
protein-RNA interactions rather than by one-to-one links 10,28, thus the net activity of a 
given SRE will be a result of the integrated effect of multiple binding factors (Fig. 1a). Such 
overlapping specificities of RNA-protein interactions may provide regulatory plasticity of 
alternative splicing, enabling a variety of relationships including regulatory redundancy or 
competition 5. In the case of DAZAP1, we show that it can promote splicing when binding 
to exon or introns (Fig. 3). However, several DAZAP1 binding motifs (i.e. three ISS groups) 
were also recognized by highly expressed splicing inhibitors of the hnRNP A1 family 10, 
thus these motifs show splicing silencer activity despite recognition by DAZAP1. The 
overlap of RNA binding specificity between splicing factors with opposite activities (e.g., 
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DAZAP1 and hnRNP A1) may also explain previous findings that the DAZAP1 binding site 
can function as splicing silencer in BRAC1 30 but as splicing enhancer in another case 31.
Another novel finding is that the CTD domain of DAZAP1 can promote splicing when 
recruited to pre-mRNA, suggesting DAZAP1 functions in a modular fashion like many 
transcription factors and splicing factors. The functional domain of SR proteins and hnRNP 
A1 were well-characterized 7,8,10,11, which allows the engineering of artificial splicing 
factors to manipulate splicing of endogenous genes 43. Recently the CTD of hnRNP H was 
identified as a new functional domain that enhances splicing when recruited to introns but 
inhibits splicing when tethered to exons 28. The proline-rich CTD of DAZAP1 presented a 
new splicing regulatory domain that can promote splicing in exonic or intronic locations 
(Fig. 3). This domain is directly recognized and phosphorylated by Erk1/2 kinase in two 
threonine sites (T269 and T315) 53 containing the TP and PxTP consensus signature of Erk 
substrates 57. We demonstrate that the phosphorylation of the CTD directly affects DAZAP1 
activity, as specific inhibition of MEK/Erk pathway or mutation of the DAZAP1 
phosphorylation sites decreased the splicing activity of DAZAP1 (Fig. 6b and 6d). Inhibition 
of Erk1/2 also shows similar effects in inhibiting splicing of DAZAP1 endogenous targets 
(Fig. 6e), suggesting that the phosphorylation of the CTD of DAZAP1 is necessary for its 
activity. The basal level of ERK phosphorylation cannot be turned off in HEK cells even 
with 20 hours of serum starvation (Supplementary Fig. 11a), thus we do not observe 
activation of DAZAP1 activity upon PMA treatment. However in HeLa cells where the Erk 
phosphorylation can be reactivated by addition of PMA, we find that the splicing of 
DAZAP1 targets can be further promoted by PMA treatment (Supplementary Fig. 11b). 
Taking together, these observations suggest that DAZAP1 activity is regulated by the 
MEK/Erk pathway, probably through phosphorylation by Erk1/2 53.
We find that the phosphorylation of DAZAP1 CTD by the MEK/Erk pathway regulates its 
nucleocytoplasmic translocation, which is also controlled by acetylation of lysine K150 on 
RRM domain 55. Acetylation and phosphorylation often co-regulate functions of RNA-
binding proteins. For example, a splicing factor SRSF2 (i.e. SC35) is acetylated at the K52 
of its RRM domain; such acetylation can inhibit phosphorylation of SRSF2 at the RS 
domain and induce its degradation 58. The finding that DAZAP1 can be regulated by both 
acetylation and phosphorylation may suggest a similar bi-partite mode of post-translational 
modification.
Our study indicates that DAZAP1 can activate splicing of alternative exons through at least 
two different mechanisms that may coexist in some cases. The DAZAP1 or its CTD can 
directly activate splicing when specifically recognizing cis-acting SREs in alternative exons 
or nearby introns. In addition, the DAZAP1 can also be recruited to pre-mRNA targets 
indirectly through binding to members of hnRNP A1 family that are well-known splicing 
inhibitors. The protein-protein interaction is mediated by the proline-rich CTD rather than 
the RRM domain of DAZAP1 (Fig. 2), consistent with recent findings that low complexity 
domains in many RNA binding proteins are probably sufficient for inter and intra molecular 
interaction 38. Therefore, for pre-mRNAs with cis-elements recognized by both DAZAP1 
and hnRNP A1, DAZAP1 can affect splicing through both mechanisms and the net outcome 
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should depend on the relative protein ratio or the subtle difference of RNA affinities 
between these two factors.
The MEK/Erk kinase cascade is a central component of the mitogenic signaling pathway. 
Here we show that the MEK/Erk pathway directly phosphorylates DAZAP1 and mediates its 
nuclear translocation and activity (Fig. 6), revealing a new molecular output of the MEK/Erk 
pathway through regulating alternative splicing. Consistently, the endogenous targets of 
DAZAP1 were significantly enriched for phospho-proteins and proteins involved in 
acetylation or ATP binding that may play important roles in cell proliferation (Fig. 5c). 
These results identify a signaling pathway in which a splicing factor is directly controlled by 
MEK/Erk mediated phosphorylation and translocation, possibly representing a new 
regulatory paradigm for other splicing factors.
As a downstream substrate for the MEK/Erk pathway, over-expression of DAZAP1 
decreased cell proliferation and migration in several assays (Fig. 7). Interestingly, the 
knockdown of DAZAP1 also decreased cell growth without significant change in cell cycle 
progression (Supplementary Fig. 10). These similar effects on cell growth by DAZAP1 
over-expression and knockdown make the rescue experiments hard to control and interpret, 
suggesting the DAZAP1 levels are very critical to normal cell proliferation. It was 
previously reported that DAZAP1 knockout mice showed a developmental delay, small 
body size and slow growth rate 26. Taken together these data suggest that the balanced level 
of DAZAP1 is critical for cell proliferation and has to be under tight regulation to maintain 
normal cell growth.
Such inhibition of cell proliferation might have subtle effects on cell cycle progression (Fig. 
7e). Apparently DAZAP1 can delay the duration of all cell cycle stages without causing cell 
death. This slow growth phenotype could possibly be achieved by decreasing cell 
metabolism, and consistently some DAZAP1 targets are known to function in metabolic 
control (Fig. 5d). Alternatively, DAZAP1 may affect splicing of multiple genes in a 
balanced fashion, thus the cells can adapt to the splicing inhibition of multiple cell cycle 
regulators by slowing down cell growth. For example, one of the DAZAP1 targets is MELK 
that regulates the cell cycle by binding and phosphorylating CDC25B 51. The DAZAP1-
controlled exon skipping in MELK leads to production of an inactive isoform lacking the 
ATP-binding region in the kinase domain, and thus may reduce MELK activity 
(Supplementary Fig. 6 and Figs. 5f and 6e). Nevertheless, the MEK/Erk/DAZAP1 pathway 
probably affects cell growth and migration by simultaneously shifting the splicing of 
multiple targets, and a thorough study of these targets will be useful in the future to provide 
molecular links between splicing regulation and cell proliferation.
In summary, this study presents general rules of how DAZAP1 controls splicing and reveals 
a new function for the MEK/Erk signaling pathway. In addition to controlling transcription, 
the MEK/Erk pathway controls splicing and maybe other post-transcriptional RNA 
processing steps by mediating the translocation of DAZAP1. As an RNA binding protein 
that shuttles between nucleus and cytoplasm, DAZAP1 might regulate both RNA translation 
(in cytoplasm) and splicing (in nucleus). Therefore the DAZAP1 nuclear/cytoplasmic 
translocation controlled by the MEK/Erk pathway is critical for maintaining the homeostasis 
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of DAZAP1 functions. Since the MEK/Erk pathway is best known for mediating the 
nuclear/cytoplasmic translocation of multiple transcription factors to control cell 




DAZAP1 was amplified by PCR from commercially available cDNA library (Human MTC 
Panel II, Clontech) using primer pair 1 and 2 (Supplementary Table 2), and then subcloned 
into Flag-pcDNA3 vector to generate Flag-DAZAP1 construct. MS2 coat protein was 
amplified using primer pairs 8 and 9 using MS2-ASF as template 59. MS2 coat protein was 
fused at 5′ end of either full length DAZAP1 (aa,1-407, using primer pair 2 and 3) or 
DAZAP1 CTD (aa,191–407, using primer pair 2 and 7) in pcDNA3. All of the constructs 
were validated by sequencing. The HA tagged version of MS2 DAZAP1/CTD was created 
by subcloning these amplicons into pCDNA3.1 using primer pair 2 and 11. Truncation 
mutants of CTD were created by PCR amplifications and followed by cloning of PCR 
products in pcDNAHAMS2 vector. Flag tagged hnRNPA1 or other hnRNPs were available 
as a reagent from our lab 10.
All the splicing reporters were constructed from a backbone vector, pZW1, which contains a 
multicloning site between two GFP exons 2 59. To construct the splicing reporter and to test 
function of intronic SREs, a constitutive exon - exon 6 of the human SIRT1 gene (Ensembl 
ID: ENSG00000096717) - was amplified together with portions of its flanking introns in 
two PCR reactions. The two PCR fragments were cloned into pZW1 to generate the 
resulting construct, pZW11, which contains a three-exon minigene with exon 1 and 3 
forming an intact GFP gene and a multicloning site at 11 bp downstream of the 5′ss of the 
test exon 2. The candidate SRE sequences and controls were inserted into reporter pZW11 
using XhoI/ApaI sites. To this end, we used a forward primer CACCTCGAG (N6) 
GGGCCCCAC and reverse primer GTGGGGCCC (N6) CTCGAGGTG that contained the 
candidate sequences (designated as ISE or ISS groups) flanked by XhoI and ApaI sites. The 
two primers were annealed, digested, and ligated into the reporter vectors.
Intronic MS2 tethering reporter was created by sub cloning MS2 hairpin loop between ApaI/
Xhol sites in previously described vector pZW2C 28. The MS2 hairpin reporters (5′ss mutant 
and branch point sites mutants) were created by subcloning the previously described reporter 
systems 41 in pcDNA3.1 between EcoR1/ Xba1 sites (using primer pairs 17 and 18).
RNA binding and SPR analysis
HnRNPA0, A1, A2 D, DL and different version of DAZAP1 were cloned into pT7HTB 
plasmid as 6xHis tagged protein. The recombinant proteins were expressed in E coli and 
purified with Ni-NTA column to homogeneity 10. The proteins were buffer exchanged to 
remove excess imidazole and were stored at 4°C for the analysis. SPR analysis was 
performed on Biacore 2000 platform using biotin labeled RNA substrates on SA-chip (GE 
Health care) 10.
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The 5′-biotynalyed RNAs were synthesized by Dharmacon and immobilized at 150 fmols 
per flow cell on a Biacore streptavidine coated chip (Sensor Chip SA, GE Health Care). A 
control flow cell was loaded with a 21nt CA-rich control sequence, and all the responses 
(RUs) were normalized to the controls. All experiments were done on Biacore 2000 
platform for at least twice in every concentration, and the data were fitted with 
BIAevaluation software. The protein is diluted to its final concentration by HBS-EP buffer 
(GE Health Care, Cat No. BR-1001-88) prior to experiments to avoid bulk shift. Data 
acquisition was performed using Kinject mode at a flow rate of 50 μl/min in the same 
running buffer. The surface is regenerated using 100 μl injection of 2M NaCl followed by 
200 μl of running buffer. The data was analyzed using 1:1 Langmuir model on Bia-
evaluation software 35.
Isothermal Titration experiments
ITC experiment was performed on auto ITC 200 (GE Health care). The purified 
recombinant proteins were resuspended in 20 mM Na-Phosphate buffer pH 7.0 with 150 
mM NaCl for ITC analysis. The full length or truncated DAZAP1 (100–150 μM in the 
injection syringe) was titrated into other hnRNPs (10–15 μM of hnRNPs in the cell). 
Injections of 2 μl DAZAP1 protein for 20 titration points were performed and the data was 
fitted using Origin for ITC software. All experiments were carried out in duplicates and the 
average experiments were reported.
Cell culture and transfection
All transfection experiments were performed in HEK 293T cells unless otherwise stated. 
Transfection of splicing reporter constructs or protein expression vectors were carried out 
using Lipofectamine 2000 (Life Technologies) or lentiviral vectors as recommended by 
instruction manuals. The cells were co-transfected with splicing reporters and protein 
expression vectors, and cultured usually for 12–48h in standard cell culture conditions as 
before and the samples for protein and RNA were collected. The protein was prepared using 
RIPA lysis buffer (Thermo Scientific), and the RNA was extracted using Trizol method 
(Life Technologies).
To co-transfect cells with expression vectors of DAZAP1 and hnRNPA1, we used fixed 
amounts of Flag tagged hnRNPA1 and increasing amounts of HA tagged MS2 CTD of 
DAZAP1. The vector encoding either of the protein was transfected in a ratios of [0.1:0.1; 
0.1:0.2; 0.1:0.4; 0.1:0.8; 0.1:1.5; 0.1:2.0 (μg: μg)] in HEK293T cells together with 0.2 μg 
splicing reporter (Fig. 4b). Titrations of hnRNPA1 Gly rich domain (MS2-Gly-A1) with 
CTD (DAZAP1) was conducted similarly by co-transfecting fixed concentrations of Flag-
MS2-Gly-A1 with increasing amounts of CTD (DAZAP1) in a ratio of 0.2:0.2 and 0.2:2.0 
(μg: μg ) (Fig. 4c).
Splicing assay with semi-quantitative RT-PCR
The semi-quantitative RT-PCR was performed using previously described protocols 60. 
Briefly, the total RNA was purified and treated with 1U of RNAase-free DNAase (Promega) 
for 1 h at 37°C, and further used as template in reverse transcription with random hexamer 
cDNA preparation kit (Applied Biosystem). To assay for the splicing outcome, the cDNA 
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was amplified in 20–25 cycles using specific primer pairs in presence of Cy5–CTP (GE 
Health care). The resultant product was separated on 6% TBE-polyacrylamide (non 
denaturing) gel in dark and further imaged and quantified on Typhoon Trio+ scanner.
Immunofluorescence microscopy
The dsRed-DAZAP1 construct is a gift from Dr. Pauline Yen, and subsequent mutations 
were generated based on this construct to generate phosphorylation mutants. To detect 
subcellular localization of DAZAP1, cells were cultured on poly L-lysine coated slide and 
transfected with dsRed-DAZAP1 and FLAG-hnRNP A1 using lipofectamine 2000. The cells 
were fixed for 20 min in 4% formaldehyde 12–16 hours after transfection, and 
permeabilized with 0.02% Triton X-100 in PBS. The slides were subsequently washed and 
blocked with 3% BSA, and incubated with anti-Flag M2 as primary antibody (Sigma) and 
then with a secondary anti-mouse goat IgG (Alexa-488, Life Technologies). Microscopy 
was performed on Olympus confocal microscope, the pictures of at least 100 cells were 
captured for quantification. For endogenous protein IF 50–80% confluent cells growing on 
cover slips are fixed in 1% formaldehyde and essentially same steps were followed as above. 
Mouse hnRNPA1, hnRNPA2 and SC35 antibodies were from Santacruz Biotech Inc. and 
Sigma respectively. DAZAP1 antibody was purchased from Santacruz Biotech Inc. The 
anti-mouse (Alexa-488) and anti-rabbit (Alexa-498) antibodies were from Life 
Technologies. All primary antibodies were used with dilution of 1:500 and fluorescent 
secondary antibodies were in the dilution range of 1:300 and diluted in BSA.
Immuno-precipitation
Standard procedures of immuno-precipitation were used. Briefly, Flag-tagged full length 
hnRNPA1 or Flag-Gly(hnRNPA1) was co-expressed with HA-tagged DAZAP1 or HA-
CTD-DAZAP1 in HEK 293T cells for 24 h. The cells were dislodged by trypsinization and 
washed with PBS (DIFCO) and incubated with a lysis buffer (50mM Tris-Cl, pH 7.4, with 
150 mM NaCl, 1mM EDTA, 1% Triton-X 100 and 2U/ml of RNaseA). The cell free extract 
was prepared by incubating cell in the above lysis buffer for 30 min at 4°C with occasional 
vortexing. Cell debris were separated by centrifugation at 15,000 rpm for 15 min. M2 flag 
beads (20 μl, purchased from Sigma) was equilibrated on a rotary shaker using 50 mM Tris-
Cl pH 7.4 with 150 mM NaCl (wash buffer). The clarified lysate was loaded on the beads 
and bound on rotary shaker for 2h at 4°C. The beads were washed with the above buffer 3 
times and then incubated with sample buffer (125 mM Tris-Cl, pH 6.8, with 4% SDS, 20% 
glycerol, and 0.004% bromophenol blue) at 70°C. The samples were loaded onto SDS-
PAGE gels immuno-blotted and detected using anti-Flag and anti-HA antibodies.
For endogenous protein IP, 50 μg anti DAZAP1 antibody (H-87: sc-67401) was 
immobilized onto protein A/G agarose beads (Santacruz Biotech) overnight at 4°C on a 
rotary shaker. HEK293T cells were grown in DMEM media at 60–80% confluence and 
lysed using lysis buffer (50mM Tris-Cl, pH 7.4, with 150 mM NaCl, 0.5% Triton-X 100 and 
2U/ml of RNaseA and protease inhibitor). Binding and washing conditions are same as 
above. Elution was performed using two 70 μl 1M glycine (pH 3.0) wash and neutralized 
with 1M Tris prior to immunoblotting. Uncropped images of Western Blots are shown in 
Supplementary Fig. 12.
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Phosphorylation studies were performed on HEK 293T cells. The cells were transfected with 
reporter and protein expression constructs and further serum starved overnight prior to 
addition of 1mM PMA (Sigma) for 40 min. The RNA was extracted using Trizol method 
and the splicing assay was performed as mentioned above. Addition of MEK inhibitor 
(U0126, Sigma) was followed 2 h post transfection and cells were collected after 16–18h-
post treatment for protein and splicing analysis.
The phospho-mutants were prepared using site directed mutagenesis kit (Quick Change II 
kit, Merck EMD). The microscopy analysis was done on Olympus confocal microscope by 
counter staining the nucleus with DAPI. DAZAP1(WT) or double mutants were made as a 
fusion construct with pDsRed2 (Clontech, pDsRed2C1). Cells were cultured on poly L-
lysine coated slide and transfected using lipofectamine 2000 and fixed using 4% 
formaldehyde. Immuno fluorescence was performed using anti-flag M2 primary antibody 
(Sigma) and subsequently detected by a secondary anti-mouse goat IgG (alexa-488, Life 
Technologies) antibody against flag tagged hnRNPA1.
Phospho DAZAP1 was resolved on Phostag™ Gels 54, immuno-blotted and detected using 
anti Flag mouse antibody (Sigma, M2 anti Flag Mouse antibody F-1804). Total Erk (C-16: 
sc-93), phospho Erk1/2 (E4: sc-7383) and DAZAP1 antibody (H-87: sc-67401) were from 
Santacruz Biotechnology Inc. hnRNPA1 antibody was purchased from Cell Signaling (Cat # 
4296). HA-tagged proteins were detected using anti mouse mAb (HRP Conjugate) from Cell 
Signaling (cat # 2999). Uncropped images of Western Blots are shown in Supplementary 
Fig. 12.
High throughput sequencing and analysis
Cell lines stably transfected with shRNA 3 (CCGG CAGGGAATACTTCAAGAAGTT 
CTCGAGAACTTCTTGAAGTATTCCCTGTTTTTG) or shRNA4 (CCGG 
CCCAGGAGCGATAACAGTAAACTCGAGTTTACTGTTATCGCTCCTGGGTTTTTTG ) 
vector (cloned into pLKO.1 TRC cloning plasmid) against DAZAP1 were created. Total 
RNA from shRNA knock down lines or a mock transfected lines were purified using 
Trizol™ method and subsequently cleaned using RNAeasy Kit (Qiagen) the bound RNA 
digested with RNAse free DNAse in column as per manufacturer’s instruction. Total RNA 
not exceeding 3 μg was further used to purify poly A RNA using Illumina TruSeq Total 
RNA Sample Prep kits with Ribo-Zero Human for removal of cytoplasmic rRNA. The 
mRNA purified was further analyzed using Bioanalyzer (Agilent Technologies) prior to 
generation of cDNA with bar coded ends. The TruSeq SR Cluster Kit v3-cBot-HS was next 
used to cluster generation reagents for the cBot cluster amplification system in a pre-mixed, 
96-well plate format that requires minimal reagent preparation. The cluster generation and 
sequencing were carried out by standard procedures in HiSeq 2000 Illumina platform, and 
we used paired end sequencing protocol to generate 100 nt read at each end.
The paired-end sequences were aligned against human genome (hg19) using MapSplice 
2.0.1.6 (default parameters) to discover splicing junctions 46. The alignments were then 
further analyzed by Cufflinks 2.0.2 to calculate the abundance (FPKM) of genes and 
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transcripts. The change of splicing isoforms were analyzed using MISO package with the 
annotation of all known alternative splicing events 48, and we filtered the results based on 
the Bayes Factor and PSI (percent spliced in) values. The Gene ontology analysis was 
performed using DAVID GO analysis software to search for enriched pathways. The genes 
in categories of phosphoproteins and acetylation from GO analysis were extracted and 
analyzed with STRING database, and the networks containing more than five nodes were 
analyses for their function annotations. A number of the targets enriched in our screen were 
tested for splicing changes by Semi-quantitative RT PCR analysis as described earlier.
To analyze the enrichment of DAZAP1 target motifs in endogenous targets, we extracted the 
skipped exons that were significantly affected by RNAi of DAZAP1. The alternative exons 
were classified according to the changes of PSI value into three categories: exons positively 
regulated by DAZAP1 (PSI value decreased by at least 0.1 upon RNAi of DAZAP1), exons 
negatively regulated by DAZAP1 (PSI value increased by at least 0.1 upon RNAi of 
DAZAP1) and exons unaffected by DAZAP1 (PSI value changed by less than 0.1). The 
exonic sequences and 400 nt intronic sequence at the downstream of exons were extracted 
for each class, and we used a standard score (RESCUE score) 52 to measure the enrichment 
of each SRE motifs.
Generation of stable cell lines
Cell culture was performed on standard DMEM media supplemented with 10% FBS (Life 
Technologies) with exception of NCI-H157 cell which were maintained on RPMI (Sigma) 
media supplemented with 10% FBS. To generate stable lines over-expressing Flag-
DAZAP1, the cDNA was cloned in pCDH expression plasmid (System Biosciences Inc) and 
was further transfected to HEK 293T cells to generate virus. The supernatant media from the 
same culture was further clarified by centrifugation to remove any cellular contaminant and 
used for infecting cell lines of interest. The infected cells were selected for stable integrants 
in puromycin containing media for at least 3 generations, prior to screening by western blot 
for the production of Flag-tagged DAZAP1 product. The knock down lines of DAZAP1 
were made by cloning stable hairpin structure targeting DAZAP1 coding region (5′-
CAGGGAATACTTCAAGAAGTT ) in pLKO.1 TRC cloning plasmid (Addgene). The 
shRNA-containing virus was made in HEK293T cells, and transduction was performed 
using standard manufacturer’s instruction. The shRNA lines were selected for 2 weeks on 
puromycin containing media and the reduction of DAZAP1 was confirmed by western blot. 
Tetracycline inducible DAZAP1 lines in HEK293T cells were generated and maintained as 
described previously 28.
Cell proliferation assay and cancer cell growth
Colony formation assay was performed by plating equal amount of cell on 100 cm tissue 
culture dish in DMEM media containing 10% FBS, the culture was followed for 2 weeks 
and fixed using 2% formaldehyde and stained with crystal violet solution at room 
temperature. The dried plates were used for estimation of colony diameter and number. 
Scratch healing assay was performed using standard protocol 61 and quantified using 
IMAGE J software. Soft agar invasion assay was performed by plating 2×104 cells on a six 
well dishes 0.35% BD Difco Noble agar (BD Diagnostic Systems) over a bottom layer of 
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0.5% BD Difco Noble agar containing RPMI, respectively. Cultures were maintained for a 
minimum of four weeks by weekly addition of fresh media to the top layer, cells were then 
stained with Crystal Violet and imaged. For flow cytometry analysis, cells growing in early 
stationary stage was collected and fixed using cold 70% ethanol and further stained with PI 
with RNAse (BD Pharmingen). Cell cycle analysis was performed using CyAn™ ADP 
Analyzer Flow Cytometer (Beckman Coulter) and analyzed using Mod Fit analysis software 
(Variety software house).
Statistical analysis
Statistical significance was tested by t-test or paired t-test using the Sigma Plot Software 
(Systat Inc.).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DAZAP1 specifically interact with multiple RNA motifs
(a). Schematic diagram of RNA-protein interactions identified by affinity chromatography. 
The binding of different intronic SREs (ISSs or ISEs) by DAZAP1 and other hnRNPs were 
presented by an overlapping network. The ISE was colored green whereas ISSs were 
represented in red. The representative sequence in each motif was also shown. (b–e). Full-
length DAZAP1 protein interacts with four different RNA sequences as indicated above 
each figure. The RNA-protein interactions were measured by SPR assay using purified 
protein and in vitro synthesized RNA oligos representing consensus motifs of each group. 
From bottom to top, the DAZAP1 concentrations were 200 nM, 300 nM, 600 nM, 1μM, 1.5 
μM and 3 μM for panels b–d, and 60 nM, 100 nM 200 nM, 500 nM, 1μM and 1.5 μM for 
panel e. (f) A diagram of DAZAP1, the two RRM domains and the proline-rich C-terminal 
domain were shown. The recombinant proteins containing RRM domains only were 
constructed according to the domain annotation. (g–i) The binding of different DAZAP1 
fragments (RRM1, RRM2 and both RRMs) to the cognate RNA target (ISS group F). The 
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experimental conditions were similar to panel b except the protein concentrations were 1 to 
5 μM for panel g and h and 50–1000 nM for panel i from bottom to top. (j) The bindings 
between different protein-RNA pairs were presented as apparent disassociation constant 
(Kd). All experiments were repeated three times unless indicated otherwise and error bars 
indicate s.d. of mean.
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Figure 2. Interaction of DAZAP1 with other hnRNPs
(a) Protein-protein interaction of full length DAZAP1 with other hnRNPs as measured by 
isothermal calorimetry (ITC) assay. All recombinant proteins were purified to homogeneity, 
and the DAZAP1 was titrated to purified full-length hnRNPA0, A1, A2 or hnRNP D in ITC 
reaction cells. Binding constants (Kd) and number of binding sites (N) were determined 
using by fitting the ITC data to Langmuir model. The means and ranges from two 
independent experiments were shown. (b) Interaction of DAZAP1 CTD with other hnRNPs 
as measured by ITC assay. Experimental conditions were identical to panel a. (c) Lack of 
interaction between DAZAP1 N-terminal fragment 2xRRMs with other hnRNPs as 
measured by ITC assay. Experimental conditions were identical to panel a.
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Figure 3. DAZAP1 promotes splicing in exonic or intronic contexts via its CTD
(a) Schematic diagram of tethering experiments using different MS2-DAZAP1 fusion 
proteins and a splicing reporter (pZW2C) containing MS2 hairpin RNA in introns 28. The 
full length or CTD of DAZAP1 protein could promote splicing when tethered to introns. The 
MS2 only, CTD, and DAZAP1 alone were used as negative controls. As additional controls, 
two canonical splicing factors, SRSF1 and hnRNP H, were also expressed as MS2 fusion 
proteins. All experiments were repeated at least three times. The exon inclusion was 
detected by semi-quantitative RT-PCR and quantified as PSI values (percent-spliced-in). 
The plot of mean and s.d. was shown below a representative gel. P values were determined 
using t-test comparing to the MS2 control. (b) Schematic diagram of tethering experiments 
using a series of splicing reporters with various splice site strengths and an exonic MS2 
site 41. The full length or CTD of DAZAP1 fused with MS2 coat protein were shown to 
promote splicing for constructs B to E. All experiments were repeated three times, and a plot 
of mean PSI and s.d. was shown below a representative gel. In all panels, **= p ≤ 0.002 ; 
*** = p ≤ 0.001; ns= not significant (t-test).
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Figure 4. DAZAP1 binds and antagonizes hnRNPA1 in splicing regulation
(a) In vivo interaction of DAZAP1 and hnRNP A1 as judged by co-immunoprecipitation 
experiments. The Flag tagged hnRNP A1 (or Gly-rich domain of A1) and HA tagged 
DAZAP1 (or its CTD) were co-expressed and pulled down using anti-Flag beads. The input 
and the precipitates were probed with western blots. Asterisks indicate the heavy and light 
chains of IgG. (b) The modular splicing reporter inserted with specific binding site of 
hnRNP A1 and DAZAP1 (ISS group F) in an alternative exon 42 was co-transfected with 
expression vectors of hnRNP A1 and CTD of DAZAP1 in different ratios, and the exon 
inclusion was detected by semi-quantitative RT-PCR and quantified. Expression vector 
alone was used as control (lane 1). The experiments were repeated at least three times, and 
the mean and s.d. was plotted below a representative gel. The protein levels were measured 
by western blots. P values were determined with paired t-test by comparing to lane 1 
(sample 2 to 3) or 4 (sample 5 to 9). (c) The splicing reporter containing a MS2 tether site in 
test exon (construct B in Fig. 3b) was co-transfected with the MS2 fusion protein of 
Gly(hnRNP A1) and the CTD of DAZAP1 in different ratios. The MS2-Gly(A1) was 
tethered to the splicing reporter, and the DAZAP1 CTD alone was used as additional 
negative control. The experiments were repeated three times, and a plot of mean and s.d. 
was shown below a representative gel. The protein levels were measured by western blots. P 
values are determined with t-test by comparing lanes 4 and 5 to lane 3. In all panels, *= p 
≤0.015; **= p ≤0.002 ; *** = p ≤0.0008; ns= not significant.
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Figure 5. Identification of endogenous alternative splicing events controlled by DAZAP1
(a) The 293T cells stably transfected with shRNA to knock down DAZAP1 (left panel). The 
cells were subsequently used for mRNA-seq analyses as shown by schematic diagram in 
right panel. (b) Upper panel, two examples of alternative exons affected by DAZAP1 
knockdown. The genes were chosen to show both the increase and decrease of exon 
inclusion, and the numbers of exon junction reads were indicated. Lower panel showed the 
numbers of different splicing events affected by DAZAP1 knockdown. SE, skipped exon; 
A3E, alternative 3′ splicing site exon; A5E, alternative 5′ splicing site exon; RI, retained 
intron; MXE, mutually exclusive exon; APA, alternative poly-A sites. (c) The gene ontology 
analyses of DAZAP1 targets with significant splicing changes after RNAi. The p values 
were plotted for each enriched functional category. (d) The functional association networks 
of DAZAP1 targets. Genes in the categories of phosphoproteins and acetylation from panel 
c were extracted and analyzed with STRING database, and the interaction networks 
containing more than five nodes were shown. The thickness of line indicates the confidence 
of interactions. The gene subgroups involved in cell cycle, metabolism and transcriptional 
control are marked. (e) Confirmation of splicing changes for one of the DAZAP1 targets 
(WAC) using semi-quantitative RT-PCR in cells with over-expression or RNAi of 
DAZAP1. The relative changes of PSI compared to controls were calculated, and the mean 
and s.d. from triplicate experiments were plotted. P values are calculated with t-test. *, 
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p≤0.03. (f) Validation of additional DAZAP1 targets using semi-quantitative RT-PCR in 
cells with over-expression or RNAi of DAZAP1. The experiments were repeated three times 
and the relative changes of PSI compared to controls were plotted with s.d. as error bars. For 
all samples, p ≤0.05 in the paired t-test by comparing PSI value of each gene to that in mock 
transfected controls (See Supplementary Fig. 6 for detail). (g) Relative enrichment of RNA 
motifs bound by DAZAP1. Relative enrichment scores were computed for each group in the 
skipped exons that were positively or negatively regulated by DAZAP1.
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Figure 6. DAZAP1 is regulated by Erk1/2 catalyzed threonine phosphorylation in the CTD
(a). A series of truncated CTDs of DAZAP1 were tethered to the exon of a splicing reporter 
to test which regions are critical for its activity. The full length DAZAP1 was used as 
positive control, and the two Erk1/2 phosphorylation sites (Thr269 and Thr315) are marked 
by red triangle. The experimental conditions were identical to Fig. 3b. The mean PSI values 
and s.d. are shown below a representative gel. P values were determined with paired t-test 
by comparing to vector-only control. In all panels, #: p ≤0.05; *= p ≤0.01; **= p ≤0.002 ; 
*** = p ≤0.0008; ns= not significant. (b) A schematic model showing that DAZAP1 activity 
is mediated by MEK/Erk pathway (left panel). The tethering experiments similar to panel a 
were conducted in cells treated with MEK/Erk activator (PMA) or inhibitor (U0126). (c). 
Phosphorylation of DAZAP1 was inhibited by two specific MEK inhibitors as judged by 
western blot with Phos-tag labeling. The phosphorylated forms of DAZAP1 were indicated 
with arrows. (d) Mutation of the two DAZAP1 threonine sites phosphorylated by Erk1/2 
abolished DAZAP1 activity as judged by tethering experiments. The experiments were 
conducted in triplicates and the mean and s.d. of PSI values are plotted below a 
representative gel. The western blot was shown on the right to confirm equal expression 
between wild type and mutated DAZAP1. The band indicated by the asterisk is likely a 
degradation product of MS2-DAZAP1. (e) Inhibition of MEK/Erk by U0126 affected the 
splicing of endogenous DAZAP1 targets FIP1L1 and MELK. A representative gel from 
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duplicated experiments and the relative changes of PSI were plotted with ranges as error 
bars. (f) Inhibition of MEK/Erk pathway affected nuclear/cytoplasmic translocation of 
DAZAP1. The cells were transfected with tagged DAZAP1 and hnRNP A1 and detected by 
corresponding antibodies. Bar, 5 μm. The percents of cells with DAZAP1 localized in 
nucleus (N), cytoplasm (C) or both compartments (N+C) were counted and plotted in the 
right panel (n=80 for each sample in two independent experiments). (g) Inhibition of 
MEK/Erk pathway affected nuclear/cytoplasmic translocation of endogenous DAZAP1. 
Scale bar, 2.5 μm.
Choudhury et al. Page 30













Figure 7. DAZAP1 regulates cell proliferation
(a) Stable over-expression of DAZAP1 in non-small cell lung carcinoma NCI-H157 cells as 
detected by western blots. Control cells are stably transfected with vector only. (b) The 
expression of DAZAP1 inhibited cell proliferation as judged by colony formation assay with 
H157 cells. A representative picture from the triplicate experiments, the means and s.d. were 
plotted. (c) DAZAP1 inhibited the anchorage independent cell growth of H157 as judged by 
soft agar assays. A representative picture from the triplicates and the quantification were 
shown. The box plot was drawn using 25 and 75 quartiles in Sigma Plot with whiskers 
indicating max and min value and dots indicating outliers. P values were determined using 
paired t-test, *=p ≤ 5.0×10−5. (d) DAZAP1 inhibited cell migration as judged by wound 
healing assay. The picture of a representative plate (left panel) and the quantification of 
percent of gap closure were shown (right panel). Data from three independent assays were 
performed error bar indicate s.d. (e) The quantification of cell cycle stages (G1, S and G2/M 
phases) in DAZAP1 over-expressed or control cells. The cell cycle stages were analyzed by 
flow-cytometry measurement of DNA content. Data from two independent flow analysis, 
error bar indicate s.d. (f) Expression of endogenous DAZAP1 protein during cell cycle as 
detected by western blots. Tubulin and canonical cell cycle markers (cyclin A1 and B1) 
were also probed as controls. (g) An integrated model for DAZAP1 function and the 
regulation of its activity through the MEK/Erk pathway.
Choudhury et al. Page 31
Nat Commun. Author manuscript; available in PMC 2014 August 27.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
